Faced with going out of business after repeated Phase II fails in a variety of tumor types for its investigational universal cancer vaccine, Norway’s Ultimovacs has been saved by compatriot Zelluna.
After a year littered with clinical failures for its cancer vaccine UV1, Ultimovacs has managed to secure survival by combining with fellow Norwegian biotech Zelluna Immunotherapy.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.
The German group could pay $3.5bn to get hold of the US firm and its two approved products.
On a quarterly earnings call that touched on Trump administration policy impacts, Merck said it is well positioned for changes coming from the new administration.
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.
Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.
In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
